Japan’s Chugai Pharmaceutical’s stock price soars, its drug can reduce the risk of death from the new crown
Visit: Alibaba Cloud “explosive special offers” theme activity-cloud server as low as 0.55 off 96 yuan/year
In a press release last Thursday, the British government stated that the results of government-funded clinical trials showed that two drugs, including tocilizumab, ” Administration within 24 hours of entering intensive care can reduce the patient’s relative risk of death by 24%.”
The statement also stated that patients receiving these drugs commonly used to treat rheumatoid arthritis “on average He left intensive care 7 to 10 days earlier.”
The British Secretary of Health Matt Hancock said that this result marks “another milestone in finding a solution to this epidemic. The government also stated that it will begin to encourage the use of tocilizumab in patients with COVID-19 admitted to the ICU, and will work with the Swiss drugmaker Roche to ensure that patients in the UK can obtain this treatment.
Tocilizumab’s trade name is Actemra or RoActemra, which is a drug developed by Roche and Chugai Pharmaceutical. Roche is now the controlling shareholder of Chugai Pharmaceutical.